Área salud
Vol. 3. Issue. 2. (April – June 2023)
Área salud
Similarities and differences between migraine and other types of headaches: Migraine mimics
Headache impacts the well-being, capacity, and functionality of an individual. Migraine is the most common type of recurrent headache for patients seeking care. It is a complex neurological disorder associated with various symptoms of sensory, […]
Área salud
The role of astrocytes with genetic mutations linked to amyotrophic lateral sclerosis
Despite advances in the understanding of genetic and molecular aspects of Amyotrophic Lateral Sclerosis (ALS), a rapidly progressive and fatal neurodegenerative disease, the exact pathogenic mechanisms are still largely unknown. For over 20 years, numerous […]
Área salud
Consensus document for lipid profile determination and reporting in Spanish clinical laboratories. What parameters should a basic lipid profile include?
Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far from being achieved in real […]
Área salud
Acute stroke in COVID-19 patients: A first year experience in a Colombian hospital
Background COVID-19 may be a new risk factor for stroke. Stroke in COVID-19 varies from 1.1 to 8.1%. Various pathophysiological pathways predispose SARS-CoV-2 infected patients to stroke. Aim To describe COVID-19 patients with acute stroke […]
Área salud
Health-related quality of life and perceived stress of informal caregivers of children and adolescents with intellectual disabilities and ADHD
Introduction Informal caregivers of children and adolescents with intellectual disabilities and attention deficit/hyperactivity disorder (ADHD) face numerous challenges. However, no study has yet compared the HRQoL of the caregivers of children and adolescents with these […]
Área salud
Monitoring response to disease-modifying treatment in multiple sclerosis
Background Standard criteria for defining suboptimal response to disease-modifying treatment (DMT) in patients with multiple sclerosis (MS) are lacking. Decision-making on how and when DMTs should be switched is challenging. The objective of the study […]